Monoclonal antibody 170

N/A

Report date: 2025/12/01 17:17:04

Base Information

Drug NameMonoclonal antibody 170
Drug Alias Name单克隆抗体170 （Biomira）Tru-Scint AD
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionRadionuclide imaging enhancersAnti-MUC1
TargetsMucin-1
Therapy Area/IndicationsOvarian NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen IncCascadian Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A